LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML

Epigenetic regulators are recurrently mutated and aberrantly expressed in acute myeloid leukemia (AML). Targeted therapies designed to inhibit these chromatin-modifying enzymes, such as the histone demethylase lysine-specific demethylase 1 (LSD1) and the histone methyltransferase DOT1L, have been de...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Cusan, Monica, Cai, Sheng F., Mohammad, Helai P., Krivtsov, Andrei, Chramiec, Alan, Loizou, Evangelia, Witkin, Matthew D., Smitheman, Kimberly N., Tenen, Daniel G., Ye, Min, Will, Britta, Steidl, Ulrich, Kruger, Ryan G., Levine, Ross L., Rienhoff, Hugh Y., Koche, Richard P., Armstrong, Scott A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2018
Konular:
Myeloid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5897868/
https://ncbi.nlm.nih.gov/pubmed/29453291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-807024
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller